<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000575</url>
  </required_header>
  <id_info>
    <org_study_id>213</org_study_id>
    <secondary_id>5U01HL075417</secondary_id>
    <nct_id>NCT00000575</nct_id>
  </id_info>
  <brief_title>Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)</brief_title>
  <acronym>CAMP</acronym>
  <official_title>Childhood Asthma Management Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>CAMP Steering Committee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy&#xD;
      compared to bronchodilator therapy on the course of asthma, particularly on lung function and&#xD;
      bronchial hyperresponsiveness, and on physical and psychosocial growth and development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Asthma is a serious chronic condition, affecting approximately 14 million Americans. People&#xD;
      with asthma experience well over 100 million days of restricted activity annually, and costs&#xD;
      for asthma care exceed $10 billion a year. Asthma is much more prevalent among children than&#xD;
      adults.&#xD;
&#xD;
      Hospitalizations for asthma have been increasing among children. For example, from 1979 to&#xD;
      1987, the hospital discharge rate with asthma as the first-listed diagnosis rose 43 percent&#xD;
      among children less than 15 years of age, from 19.8 to 28.4 discharges per 10,000 population.&#xD;
&#xD;
      Death rates for asthma are greater in Blacks than in whites, and the difference is&#xD;
      increasing. In 1979, Blacks of both sexes were about twice as likely to die from asthma as&#xD;
      whites. Over the past decade this ratio has increased, and by 1987 the asthma death rate was&#xD;
      almost three times greater among Blacks than whites. In children, these mortality differences&#xD;
      between Blacks and whites are even more striking.&#xD;
&#xD;
      Current knowledge about the epidemiology and natural history of childhood asthma is&#xD;
      incomplete, but the relationship between asthma early in life and development of chronic&#xD;
      obstructive pulmonary disease (COPD) in adulthood is becoming more apparent. Asthmatic&#xD;
      children with persistent and severe asthma symptoms have lower levels of lung function by&#xD;
      young adulthood than those with milder disease. Recent longitudinal studies have confirmed a&#xD;
      decrease in rate of growth of lung function as measured by FEV1 among symptomatic (primarily&#xD;
      wheeze) children compared to asymptomatic children. Among persons who develop COPD, initial&#xD;
      level of lung function is the strongest predictor of subsequent rapid decline of ventilatory&#xD;
      function.&#xD;
&#xD;
      Thus, less than maximally attained levels of lung function among children with asthma may&#xD;
      predispose them to greater than normal decline of lung function later in life. Although the&#xD;
      long-term effect of treatment on the course of asthma is not known, the treatment goal of&#xD;
      decreasing bronchial hyperresponsiveness and maximizing lung function and growth during&#xD;
      childhood may have a beneficial effect on lung health throughout life and prevent progression&#xD;
      to irreversible airflow obstruction.&#xD;
&#xD;
      Two classes of medications are currently available for treatment of&#xD;
      inflammation--corticosteroids and cromolyn sodium. Inhaled corticosteroids have significantly&#xD;
      fewer side effects than systemic administration. Corticosteroids do not inhibit the early&#xD;
      asthmatic response, but are effective in suppressing the inflammation and bronchial&#xD;
      hyperresponsiveness of the late phase response. Long-term studies of inhaled corticosteroids&#xD;
      have shown beneficial effects on lung function as measured by FEV1. However, there has been&#xD;
      concern about possible effects of long-term use of inhaled corticosteroids. Although&#xD;
      epidemiological studies of the use of inhaled corticosteroids have shown no significant&#xD;
      adverse effects, large-scale randomized controlled studies of their effects on children's&#xD;
      growth and development are needed.&#xD;
&#xD;
      When CAMP was initiated in the United States, bronchodilator treatment was the most common&#xD;
      approach to therapy. Two classes of bronchodilators, inhaled beta-2-adrenergic agonists and&#xD;
      oral theophylline, are most frequently prescribed for asthma. To date, no randomized,&#xD;
      controlled studies have compared the two classes of anti-inflammatory medications to each&#xD;
      other and to bronchodilator therapy on the course of asthma.&#xD;
&#xD;
      The initiative was proposed by the Pulmonary Disease Advisory Committee working group in&#xD;
      October 1987 and approved by the full committee at the February 1988 meeting and by the&#xD;
      National Heart, Lung, and Blood Advisory Council in May 1990. The Request for Proposals was&#xD;
      released in October 1990. Awards were made in September 1991.&#xD;
&#xD;
      DESIGN NARRATIVE:&#xD;
&#xD;
      Children were randomized to one of three treatment groups to receive either: inhaled&#xD;
      albuterol alone, albuterol with inhaled budesonide, albuterol with nedocromil. Upon&#xD;
      randomization, data were collected on demographic factors, physical and psychosocial&#xD;
      development, clinical factors including medical history and extent of allergies, and quality&#xD;
      of life factors including limitation of activity, absenteeism from school, emergency room&#xD;
      visits, and hospitalizations. All subjects received a common educational program, differing&#xD;
      only in the information presented regarding the medication used by the subjects. Each subject&#xD;
      was given a standard protocol for dealing with asthma attacks. All subjects were treated and&#xD;
      followed for five years with quarterly visits yearly. Recruitment began in July 1993 and&#xD;
      ended in June 1995 with the accrual of 1,041 subjects.&#xD;
&#xD;
      The study has been extended through June 2011 through three funding phases to observe the&#xD;
      subjects but not provide asthma treatment. This will allow CAMP to (1.) determine the full&#xD;
      impact of 4 to 6 years of anti-inflammatory therapy on attaining maximal lung function and&#xD;
      final height; (2.) examine the natural history of asthma through age 26; and (3.) define&#xD;
      patterns of reduced lung function growth and early decline of lung function in young adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1991</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Function as Measured by Normalized FEV1 Over a 4-6 Year Period</measure>
    <time_frame>At the end of treatment, 4-6 years from baseline assessment</time_frame>
    <description>Change in FEV1 % of predicted, post-bronchodilator use, from baseline to the end of treatment (4-6 years after randomization). Percent predicted determined from three separate published sets of reference equations for white, black, and Hispanic children - see NEJM 343: 1054-1062, 2000 for more details and references.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchial Responsiveness to Serial Methacholine Concentrations Inhaled Into the Lungs</measure>
    <time_frame>4-6 years from baseline</time_frame>
    <description>Bronchial responsiveness to serial concentrations of inhaled methacholine solution (mg/ml) as measured by serial ratios of follow-up to baseline FEV1 (forced volume of air expired from the lungs in one second). A dose-response curve is calculated from the serial ratios in relation to the serial concentrations to determine PC20, the concentration associated with a 20% drop from baseline in FEV1; this PC20 is the outcome measure with units mg/ml of methacholine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Rate of Asthma Free Days</measure>
    <time_frame>4-6 years from baseline</time_frame>
    <description>Change from baseline proportion of days without asthma symptoms or other asthma related events to proportion of days during the 4-6 years of follow-up. Asthma free days were determined from daily asthma diaries kept from baseline to the end of treatment, 4-6 years later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Urgent Care for Asthma</measure>
    <time_frame>4-6 years from baseline</time_frame>
    <description>Counts during the period of treatment (4-6 years) of visits to emergency rooms or equivalent urgent care settings for asthma treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>4-6 years from baseline</time_frame>
    <description>Counts of deaths from asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Height From Baseline to End of Treatment, 4-6 Years Later</measure>
    <time_frame>4-6 years from baseline</time_frame>
    <description>Change in standing height from baseline to end of treatment. Standing height is measured three times without shoes using a calibrated Harpenden stadiometer; the average of the three repeated heights to the nearest 0.1 cm is the height measure at either baseline or end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Depression Scale -- Children's Depression Inventory</measure>
    <time_frame>4-6 years from baseline</time_frame>
    <description>Change in total score on the Children's Depression Inventory from baseline to the end of treatment, 4-6 years later. The total score ranges from 0-54 with higher scores indicating greater levels of depression.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1041</enrollment>
  <condition>Asthma</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>1 Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Nedocromil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.</description>
    <arm_group_label>3 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedocromil</intervention_name>
    <description>Four 2 mg puffs bid + two 90 Og puffs albuterol prn</description>
    <arm_group_label>2 Nedocromil</arm_group_label>
    <other_name>Tilade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Two 100 Og puffs bid + two 90 Og puffs albuterol prn.</description>
    <arm_group_label>1 Budesonide</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age 5 to 12 years at time of screening&#xD;
&#xD;
          -  Chronic asthma as evidenced by one or more of the following historical findings for at&#xD;
             least 6 months during the past year:&#xD;
&#xD;
          -  Asthma symptoms at least 2 times per week&#xD;
&#xD;
          -  2 or more usages per week of an inhaled bronchodilator&#xD;
&#xD;
          -  Daily asthma medication&#xD;
&#xD;
          -  Current asthma symptoms either by diary symptom code of 1 or greater or am or pm PEFR&#xD;
             less than 80% of personal best post-bronchodilator value by diary, on 8 or more days&#xD;
             during the prn screening period&#xD;
&#xD;
          -  Methacholine sensitivity: estimated PC20 FEV1 less than or equal to 12.5 mg/ml&#xD;
&#xD;
          -  Consent of guardian and assent of child&#xD;
&#xD;
          -  Ability to comply with trial for 5 - 6.5 years&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Presence of one or more of the following confounding or complicating problems:&#xD;
&#xD;
          -  Any other active pulmonary disease&#xD;
&#xD;
          -  Any chronic condition presumed to interfere with the successful completion of the&#xD;
             project or confound its interpretation&#xD;
&#xD;
          -  Pulmonary function testing findings suggesting a ventilatory defect other than asthma,&#xD;
             or evidence of existing irreversible lung damage&#xD;
&#xD;
          -  Severe chronic sinusitis or nasal polyposis&#xD;
&#xD;
          -  Introduction of or a change in allergen immunotherapy within the past month&#xD;
&#xD;
          -  Use of more than 4 sprays of nasal steroids daily (only beclomethasone allowed)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current use of metoclopramide, ranitidine, or cimetidine&#xD;
&#xD;
          -  Treatment for gastroesophageal reflux&#xD;
&#xD;
          -  Participation in another drug study&#xD;
&#xD;
          -  Evidence of severe asthma as indicated by one or more of the following:&#xD;
&#xD;
          -  Two or more hospitalizations for asthma in the past year&#xD;
&#xD;
          -  Six or more steroid bursts in the past year&#xD;
&#xD;
          -  Demonstrated need for continuous use of glucocorticoids, either oral or inhaled&#xD;
&#xD;
          -  When off inhaled O2-agonist for more than 4 hrs and theophylline for more than 24 hrs,&#xD;
             FEV1 less than 65% predicted&#xD;
&#xD;
          -  Intubation for asthma at any time in the past&#xD;
&#xD;
          -  Need for 9 or more puffs/day of albuterol for each of 3 consecutive days (excluding&#xD;
             preventive use prior to exercise), or nocturnal asthma awakenings more than 1.5 times&#xD;
             per week on average, or average diary card symptom code greater than 2, or requirement&#xD;
             for other medications to control asthma, during prn screening period&#xD;
&#xD;
          -  Inability to perform 3 acceptable FVC maneuvers of which at least 2 reproducible FEV1s&#xD;
             are within 10% of the largest FEV1&#xD;
&#xD;
          -  Inability to complete the methacholine challenge or methacholine PC20 FEV1 greater&#xD;
             than 12.5 mg/ml&#xD;
&#xD;
          -  Evidence that patient or family may be unreliable or non-compliant or may move from&#xD;
             the metropolitan area before trial completion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>N. F. Adkinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Fuhlbrigge, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. W. Kelly, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Padmaja Subbarao, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asthma, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Strunk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanley Szefler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Tonascia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Zeiger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <reference>
    <citation>Design and implementation of a patient education center for the Childhood Asthma Management Program. Childhood Asthma Management Program Research Group. Ann Allergy Asthma Immunol. 1998 Dec;81(6):571-81.</citation>
    <PMID>9892029</PMID>
  </reference>
  <reference>
    <citation>Recruitment of participants in the childhood Asthma Management Program (CAMP). I. Description of methods: Childhood Asthma Management Program Research Group. J Asthma. 1999 May;36(3):217-37.</citation>
    <PMID>10350219</PMID>
  </reference>
  <reference>
    <citation>The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group. Control Clin Trials. 1999 Feb;20(1):91-120.</citation>
    <PMID>10027502</PMID>
  </reference>
  <reference>
    <citation>Zeiger RS, Dawson C, Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):376-87. doi: 10.1016/s0091-6749(99)70460-4.</citation>
    <PMID>10069869</PMID>
  </reference>
  <reference>
    <citation>Nelson HS, Szefler SJ, Jacobs J, Huss K, Shapiro G, Sternberg AL. The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):775-85. doi: 10.1016/s0091-6749(99)70287-3.</citation>
    <PMID>10518821</PMID>
  </reference>
  <reference>
    <citation>Bender BG, Annett RD, Ikle D, DuHamel TR, Rand C, Strunk RC. Relationship between disease and psychological adaptation in children in the Childhood Asthma Management Program and their families. CAMP Research Group. Arch Pediatr Adolesc Med. 2000 Jul;154(7):706-13. doi: 10.1001/archpedi.154.7.706.</citation>
    <PMID>10891023</PMID>
  </reference>
  <reference>
    <citation>Larsen GL. Focusing on childhood asthma: the childhood asthma management program (CAMP). J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):371-3. doi: 10.1016/s0091-6749(99)70458-6. No abstract available.</citation>
    <PMID>10069867</PMID>
  </reference>
  <reference>
    <citation>Weiss ST, Van Natta ML, Zeiger RS. Relationship between increased airway responsiveness and asthma severity in the childhood asthma management program. Am J Respir Crit Care Med. 2000 Jul;162(1):50-6. doi: 10.1164/ajrccm.162.1.9811005.</citation>
    <PMID>10903219</PMID>
  </reference>
  <reference>
    <citation>Annett RD, Aylward EH, Lapidus J, Bender BG, DuHamel T. Neurocognitive functioning in children with mild and moderate asthma in the childhood asthma management program. The Childhood Asthma Management Program (CAMP) Research Group. J Allergy Clin Immunol. 2000 Apr;105(4):717-24. doi: 10.1067/mai.2000.105226.</citation>
    <PMID>10756221</PMID>
  </reference>
  <reference>
    <citation>Childhood Asthma Management Program Research Group; Szefler S, Weiss S, Tonascia J, Adkinson NF, Bender B, Cherniack R, Donithan M, Kelly HW, Reisman J, Shapiro GG, Sternberg AL, Strunk R, Taggart V, Van Natta M, Wise R, Wu M, Zeiger R. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000 Oct 12;343(15):1054-63. doi: 10.1056/NEJM200010123431501.</citation>
    <PMID>11027739</PMID>
  </reference>
  <reference>
    <citation>Huss K, Adkinson NF Jr, Eggleston PA, Dawson C, Van Natta ML, Hamilton RG. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. J Allergy Clin Immunol. 2001 Jan;107(1):48-54. doi: 10.1067/mai.2001.111146.</citation>
    <PMID>11149990</PMID>
  </reference>
  <reference>
    <citation>Yu O, Sheppard L, Lumley T, Koenig JQ, Shapiro GG. Effects of ambient air pollution on symptoms of asthma in Seattle-area children enrolled in the CAMP study. Environ Health Perspect. 2000 Dec;108(12):1209-14. doi: 10.1289/ehp.001081209.</citation>
    <PMID>11133403</PMID>
  </reference>
  <reference>
    <citation>Annett RD, Bender BG, Lapidus J, Duhamel TR, Lincoln A. Predicting children's quality of life in an asthma clinical trial: what do children's reports tell us? J Pediatr. 2001 Dec;139(6):854-61. doi: 10.1067/mpd.2001.119444.</citation>
    <PMID>11743513</PMID>
  </reference>
  <reference>
    <citation>Weiss ST, Horner A, Shapiro G, Sternberg AL; Childhood Asthma Management Program (CAMP) Research Group. The prevalence of environmental exposure to perceived asthma triggers in children with mild-to-moderate asthma: data from the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol. 2001 Apr;107(4):634-40. doi: 10.1067/mai.2001.113869.</citation>
    <PMID>11295651</PMID>
  </reference>
  <reference>
    <citation>Strunk RC, Sternberg AL, Bacharier LB, Szefler SJ. Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program. J Allergy Clin Immunol. 2002 Sep;110(3):395-403. doi: 10.1067/mai.2002.127433.</citation>
    <PMID>12209085</PMID>
  </reference>
  <reference>
    <citation>DeMeo DL, Lange C, Silverman EK, Senter JM, Drazen JM, Barth MJ, Laird N, Weiss ST. Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program. Genet Epidemiol. 2002 Nov;23(4):335-48. doi: 10.1002/gepi.10182.</citation>
    <PMID>12432502</PMID>
  </reference>
  <reference>
    <citation>Strunk RC, Bender B, Young DA, Sagel S, Glynn E, Caesar M, Lawhon C. Predictors of protocol adherence in a pediatric asthma clinical trial. J Allergy Clin Immunol. 2002 Oct;110(4):596-602. doi: 10.1067/mai.2002.128803.</citation>
    <PMID>12373267</PMID>
  </reference>
  <reference>
    <citation>Kelly HW, Strunk RC, Donithan M, Bloomberg GR, McWilliams BC, Szefler S; Childhood Asthma Management Program (CAMP). Growth and bone density in children with mild-moderate asthma: a cross-sectional study in children entering the Childhood Asthma Management Program (CAMP). J Pediatr. 2003 Mar;142(3):286-91. doi: 10.1067/mpd.2003.86.</citation>
    <PMID>12640377</PMID>
  </reference>
  <reference>
    <citation>Bacharier LB, Dawson C, Bloomberg GR, Bender B, Wilson L, Strunk RC; Childhood Asthma Management Program Research Group. Hospitalization for asthma: atopic, pulmonary function, and psychological correlates among participants in the Childhood Asthma Management Program. Pediatrics. 2003 Aug;112(2):e85-92. doi: 10.1542/peds.112.2.e85.</citation>
    <PMID>12897312</PMID>
  </reference>
  <reference>
    <citation>Tantisira KG, Litonjua AA, Weiss ST, Fuhlbrigge AL; Childhood Asthma Management Program Research Group. Association of body mass with pulmonary function in the Childhood Asthma Management Program (CAMP). Thorax. 2003 Dec;58(12):1036-41. doi: 10.1136/thorax.58.12.1036.</citation>
    <PMID>14645968</PMID>
  </reference>
  <reference>
    <citation>Silverman EK, Kwiatkowski DJ, Sylvia JS, Lazarus R, Drazen JM, Lange C, Laird NM, Weiss ST. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol. 2003 Nov;112(5):870-6. doi: 10.1016/s0091-6749(03)02023-2.</citation>
    <PMID>14610472</PMID>
  </reference>
  <reference>
    <citation>Lange C, Lyon H, DeMeo D, Raby B, Silverman EK, Weiss ST. A new powerful non-parametric two-stage approach for testing multiple phenotypes in family-based association studies. Hum Hered. 2003;56(1-3):10-7. doi: 10.1159/000073728.</citation>
    <PMID>14614234</PMID>
  </reference>
  <reference>
    <citation>Slaughter JC, Lumley T, Sheppard L, Koenig JQ, Shapiro GG. Effects of ambient air pollution on symptom severity and medication use in children with asthma. Ann Allergy Asthma Immunol. 2003 Oct;91(4):346-53. doi: 10.1016/S1081-1206(10)61681-X.</citation>
    <PMID>14582813</PMID>
  </reference>
  <reference>
    <citation>Bender BG, Ellison MC, Gleason M, Murphy JR, Sundstrom DA, Szefler SJ. Minimizing attrition in a long-term clinical trial of pediatric asthma. Ann Allergy Asthma Immunol. 2003 Aug;91(2):168-76. doi: 10.1016/S1081-1206(10)62173-4.</citation>
    <PMID>12952111</PMID>
  </reference>
  <reference>
    <citation>Raby BA, Silverman EK, Lazarus R, Lange C, Kwiatkowski DJ, Weiss ST. Chromosome 12q harbors multiple genetic loci related to asthma and asthma-related phenotypes. Hum Mol Genet. 2003 Aug 15;12(16):1973-9. doi: 10.1093/hmg/ddg208.</citation>
    <PMID>12913068</PMID>
  </reference>
  <reference>
    <citation>Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, Schaid DJ. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered. 2003;55(1):56-65. doi: 10.1159/000071811.</citation>
    <PMID>12890927</PMID>
  </reference>
  <reference>
    <citation>Bacharier LB, Raissy HH, Wilson L, McWilliams B, Strunk RC, Kelly HW. Long-term effect of budesonide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma. Pediatrics. 2004 Jun;113(6):1693-9. doi: 10.1542/peds.113.6.1693.</citation>
    <PMID>15173493</PMID>
  </reference>
  <reference>
    <citation>Covar RA, Spahn JD, Murphy JR, Szefler SJ; Childhood Asthma Management Program Research Group. Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med. 2004 Aug 1;170(3):234-41. doi: 10.1164/rccm.200308-1174OC. Epub 2004 Mar 17.</citation>
    <PMID>15028558</PMID>
  </reference>
  <reference>
    <citation>Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, Liggett SB, Gelfand EW, Rosenwasser LJ, Richter B, Israel E, Wechsler M, Gabriel S, Altshuler D, Lander E, Drazen J, Weiss ST. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004 Jul 1;13(13):1353-9. doi: 10.1093/hmg/ddh149. Epub 2004 May 5.</citation>
    <PMID>15128701</PMID>
  </reference>
  <reference>
    <citation>Lazarus R, Raby BA, Lange C, Silverman EK, Kwiatkowski DJ, Vercelli D, Klimecki WJ, Martinez FD, Weiss ST. TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med. 2004 Sep 15;170(6):594-600. doi: 10.1164/rccm.200404-491OC. Epub 2004 Jun 16.</citation>
    <PMID>15201134</PMID>
  </reference>
  <reference>
    <citation>Covar RA, Szefler SJ, Martin RJ, Sundstrom DA, Silkoff PE, Murphy J, Young DA, Spahn JD. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr. 2003 May;142(5):469-75. doi: 10.1067/mpd.2003.187.</citation>
    <PMID>12756375</PMID>
  </reference>
  <reference>
    <citation>Covar RA, Spahn JD, Martin RJ, Silkoff PE, Sundstrom DA, Murphy J, Szefler SJ. Safety and application of induced sputum analysis in childhood asthma. J Allergy Clin Immunol. 2004 Sep;114(3):575-82. doi: 10.1016/j.jaci.2004.06.036.</citation>
    <PMID>15356559</PMID>
  </reference>
  <reference>
    <citation>Randolph AG, Lange C, Silverman EK, Lazarus R, Silverman ES, Raby B, Brown A, Ozonoff A, Richter B, Weiss ST. The IL12B gene is associated with asthma. Am J Hum Genet. 2004 Oct;75(4):709-15. doi: 10.1086/424886. Epub 2004 Aug 20.</citation>
    <PMID>15322986</PMID>
  </reference>
  <reference>
    <citation>Randolph AG, Lange C, Silverman EK, Lazarus R, Weiss ST. Extended haplotype in the tumor necrosis factor gene cluster is associated with asthma and asthma-related phenotypes. Am J Respir Crit Care Med. 2005 Sep 15;172(6):687-92. doi: 10.1164/rccm.200501-122OC. Epub 2005 Jun 23.</citation>
    <PMID>15976383</PMID>
  </reference>
  <reference>
    <citation>Annett RD, Stansbury K, Kelly HW, Strunk RC. Association of hypothalamic-pituitary-adrenal axis function with neuropsychological performance in children with mild/moderate asthma. Child Neuropsychol. 2005 Aug;11(4):333-48. doi: 10.1080/09297040490916929.</citation>
    <PMID>16051562</PMID>
  </reference>
  <reference>
    <citation>Raby BA, Hwang ES, Van Steen K, Tantisira K, Peng S, Litonjua A, Lazarus R, Giallourakis C, Rioux JD, Sparrow D, Silverman EK, Glimcher LH, Weiss ST. T-bet polymorphisms are associated with asthma and airway hyperresponsiveness. Am J Respir Crit Care Med. 2006 Jan 1;173(1):64-70. doi: 10.1164/rccm.200503-505OC. Epub 2005 Sep 22.</citation>
    <PMID>16179640</PMID>
  </reference>
  <reference>
    <citation>Raby BA, Van Steen K, Celedon JC, Litonjua AA, Lange C, Weiss ST; CAMP Research Group. Paternal history of asthma and airway responsiveness in children with asthma. Am J Respir Crit Care Med. 2005 Sep 1;172(5):552-8. doi: 10.1164/rccm.200501-010OC. Epub 2005 Jun 3.</citation>
    <PMID>15937295</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 27, 1999</study_first_submitted>
  <study_first_submitted_qc>October 27, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 1999</study_first_posted>
  <results_first_submitted>October 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 3, 2014</results_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>James Tonascia</investigator_full_name>
    <investigator_title>Principal Investigator, CAMP Data Coordinating Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nedocromil</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between December 1993 and September 1995, 1041 children from 5 through 12 years of age with mild to moderate asthma at eight clinical centers (two HMOs associated with academic or research institutions and six located in specialty practices within academic or research institutions) were enrolled.</recruitment_details>
      <pre_assignment_details>Patients were required to stop all asthma medications except as needed albuterol (prednisone could be used for asthma exacerbations) at the close of the second screening visit. Also at this time, patients began keeping a daily diary of asthma signs and symptoms, medications, school absences, and physician contacts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Budesonide</title>
          <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
        </group>
        <group group_id="P2">
          <title>2 Nedocromil</title>
          <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
        </group>
        <group group_id="P3">
          <title>3 Placebo</title>
          <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Budesonide</title>
          <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
        </group>
        <group group_id="B2">
          <title>2 Nedocromil</title>
          <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
        </group>
        <group group_id="B3">
          <title>3 Placebo</title>
          <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="311"/>
            <count group_id="B2" value="312"/>
            <count group_id="B3" value="418"/>
            <count group_id="B4" value="1041"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="311"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="418"/>
                    <measurement group_id="B4" value="1041"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" spread="2.1"/>
                    <measurement group_id="B2" value="8.8" spread="2.1"/>
                    <measurement group_id="B3" value="9.0" spread="2.2"/>
                    <measurement group_id="B4" value="8.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="184"/>
                    <measurement group_id="B4" value="420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="234"/>
                    <measurement group_id="B4" value="621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="368"/>
                    <measurement group_id="B4" value="916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Function as Measured by Normalized FEV1 Over a 4-6 Year Period</title>
        <description>Change in FEV1 % of predicted, post-bronchodilator use, from baseline to the end of treatment (4-6 years after randomization). Percent predicted determined from three separate published sets of reference equations for white, black, and Hispanic children - see NEJM 343: 1054-1062, 2000 for more details and references.</description>
        <time_frame>At the end of treatment, 4-6 years from baseline assessment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Budesonide</title>
            <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
          </group>
          <group group_id="O2">
            <title>2 Nedocromil</title>
            <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function as Measured by Normalized FEV1 Over a 4-6 Year Period</title>
          <description>Change in FEV1 % of predicted, post-bronchodilator use, from baseline to the end of treatment (4-6 years after randomization). Percent predicted determined from three separate published sets of reference equations for white, black, and Hispanic children - see NEJM 343: 1054-1062, 2000 for more details and references.</description>
          <units>percentage of predicted value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="9.6"/>
                    <measurement group_id="O2" value="-0.5" spread="9.6"/>
                    <measurement group_id="O3" value="-0.1" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchial Responsiveness to Serial Methacholine Concentrations Inhaled Into the Lungs</title>
        <description>Bronchial responsiveness to serial concentrations of inhaled methacholine solution (mg/ml) as measured by serial ratios of follow-up to baseline FEV1 (forced volume of air expired from the lungs in one second). A dose-response curve is calculated from the serial ratios in relation to the serial concentrations to determine PC20, the concentration associated with a 20% drop from baseline in FEV1; this PC20 is the outcome measure with units mg/ml of methacholine.</description>
        <time_frame>4-6 years from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Budesonide</title>
            <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
          </group>
          <group group_id="O2">
            <title>2 Nedocromil</title>
            <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchial Responsiveness to Serial Methacholine Concentrations Inhaled Into the Lungs</title>
          <description>Bronchial responsiveness to serial concentrations of inhaled methacholine solution (mg/ml) as measured by serial ratios of follow-up to baseline FEV1 (forced volume of air expired from the lungs in one second). A dose-response curve is calculated from the serial ratios in relation to the serial concentrations to determine PC20, the concentration associated with a 20% drop from baseline in FEV1; this PC20 is the outcome measure with units mg/ml of methacholine.</description>
          <units>mg/ml of methacholine</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="305"/>
                <count group_id="O3" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.3"/>
                    <measurement group_id="O2" value="1.8" spread="3.3"/>
                    <measurement group_id="O3" value="1.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Rate of Asthma Free Days</title>
        <description>Change from baseline proportion of days without asthma symptoms or other asthma related events to proportion of days during the 4-6 years of follow-up. Asthma free days were determined from daily asthma diaries kept from baseline to the end of treatment, 4-6 years later.</description>
        <time_frame>4-6 years from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Budesonide</title>
            <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
          </group>
          <group group_id="O2">
            <title>2 Nedocromil</title>
            <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Rate of Asthma Free Days</title>
          <description>Change from baseline proportion of days without asthma symptoms or other asthma related events to proportion of days during the 4-6 years of follow-up. Asthma free days were determined from daily asthma diaries kept from baseline to the end of treatment, 4-6 years later.</description>
          <units>days per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="10.2"/>
                    <measurement group_id="O2" value="9.3" spread="10.2"/>
                    <measurement group_id="O3" value="9.3" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Urgent Care for Asthma</title>
        <description>Counts during the period of treatment (4-6 years) of visits to emergency rooms or equivalent urgent care settings for asthma treatment.</description>
        <time_frame>4-6 years from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Budesonide</title>
            <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
          </group>
          <group group_id="O2">
            <title>2 Nedocromil</title>
            <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Urgent Care for Asthma</title>
          <description>Counts during the period of treatment (4-6 years) of visits to emergency rooms or equivalent urgent care settings for asthma treatment.</description>
          <units>rate per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Counts of deaths from asthma.</description>
        <time_frame>4-6 years from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Budesonide</title>
            <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
          </group>
          <group group_id="O2">
            <title>2 Nedocromil</title>
            <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Counts of deaths from asthma.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Height From Baseline to End of Treatment, 4-6 Years Later</title>
        <description>Change in standing height from baseline to end of treatment. Standing height is measured three times without shoes using a calibrated Harpenden stadiometer; the average of the three repeated heights to the nearest 0.1 cm is the height measure at either baseline or end of treatment.</description>
        <time_frame>4-6 years from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Budesonide</title>
            <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
          </group>
          <group group_id="O2">
            <title>2 Nedocromil</title>
            <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Height From Baseline to End of Treatment, 4-6 Years Later</title>
          <description>Change in standing height from baseline to end of treatment. Standing height is measured three times without shoes using a calibrated Harpenden stadiometer; the average of the three repeated heights to the nearest 0.1 cm is the height measure at either baseline or end of treatment.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="5.4"/>
                    <measurement group_id="O2" value="23.7" spread="5.4"/>
                    <measurement group_id="O3" value="23.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Depression Scale -- Children's Depression Inventory</title>
        <description>Change in total score on the Children's Depression Inventory from baseline to the end of treatment, 4-6 years later. The total score ranges from 0-54 with higher scores indicating greater levels of depression.</description>
        <time_frame>4-6 years from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Budesonide</title>
            <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
          </group>
          <group group_id="O2">
            <title>2 Nedocromil</title>
            <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Depression Scale -- Children's Depression Inventory</title>
          <description>Change in total score on the Children's Depression Inventory from baseline to the end of treatment, 4-6 years later. The total score ranges from 0-54 with higher scores indicating greater levels of depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="5.1"/>
                    <measurement group_id="O2" value="-1.8" spread="5.1"/>
                    <measurement group_id="O3" value="-2.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Budesonide</title>
          <description>Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn</description>
        </group>
        <group group_id="E2">
          <title>2 Nedocromil</title>
          <description>Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn</description>
        </group>
        <group group_id="E3">
          <title>3 Placebo</title>
          <description>Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric (hallucinations)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal (low bone mineral density, back pain)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Phsychiatric (behavior)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory (cough, wheeze, chest tightness, croup)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alice Sternberg</name_or_title>
      <organization>Johns Hopkins Bloomberg School of Public Health, Dept of Epidemiology</organization>
      <phone>410-955-3752</phone>
      <email>asternbe@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

